Beneficial effects of PCSK9 inhibition with alirocumab in familial hypercholesterolemia involve modulation of new immune players

  1. Marques, P.
  2. Domingo, E.
  3. Rubio, A.
  4. Martinez-Hervás, S.
  5. Ascaso, J.F.
  6. Piqueras, L.
  7. Real, J.T.
  8. Sanz, M.-J.
Revista:
Biomedicine and Pharmacotherapy

ISSN: 1950-6007,  0753-3322

Any de publicació: 2022

Volum: 145

Tipus: Article

DOI: 10.1016/J.BIOPHA.2021.112460 GOOGLE SCHOLAR lock_openAccés obert editor
Font de les dades: Scopus